Autopsy and Case Reports
https://autopsyandcasereports.org/article/doi/10.4322/acr.2015.022
Autopsy and Case Reports
Article / Autopsy Case Report

The infantile-onset form of Pompe disease: an autopsy diagnosis

Otávio César Cruz dos Santos; Regina Schultz

Downloads: 19
Views: 405

Abstract

Pompe disease (PD) is a rare, inherited autosomal recessive metabolic disorder caused by the deficiency of the lysosomal acid alpha-glucosidase (GAA) enzyme described in 1932 by the Dutch pathologist Joannes Cassianus Pompe. The prevalence of PD ranges from 1:40,000 to 1:300,000 births and depends on geographic and ethnic factors. Clinical manifestations may vary from a rapidly progressive disabling disease with cardiomegaly, hepatomegaly, weakness, generalized hypotonia, and death within the first year of life, to a mild presentation characterized by slowly progressive myopathy predominantly involving the skeletal muscles. The laboratory diagnostic gold standard is represented by the determination of the alpha-glucosidase activity. However, the muscle histology may also yield the diagnosis by evaluating the tissular glycogen accumulation. Until recently, supportive measures constituted the unique available therapy. Currently, the administration of the recombinant GAA is being used with promising results. The authors present the case of a 5-month-old boy, previously diagnosed with hypertrophic cardiomyopathy since the age of 2 months, who presented acute heart failure accompanied by biventricular dilation followed by refractory shock and death. The autopsy findings confirmed the glycogen-accumulation disease.
 

Keywords

Autopsy, Glycogen Storage Disease Type II, GAA protein, human, Cardiomyopathy, Diagnosis

References

Pryce JW, Bamber AR, Ashworth MT, Kiho L, Malone M, Sebire NJ. Reference ranges for organ weights of infants at autopsy: results of >1,000 consecutive cases from a single centre. BMC Clin Pathol. 2014;14(1):18. 10.1186/1472-6890-14-18.24822034

Werneck LC, Lorenzoni PJ, Kay CS, Scola RH. Muscle biopsy in Pompe disease. Arq Neuropsiquiatr. 2013;71(5):284-9. 10.1590/0004-282X20130022.23689405

Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenesis type II. Neurology. 2008;71(23, Suppl 2):S4-11. 10.1212/WNL.0b013e31818da91e.19047572

Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177. 10.3389/fnagi.2014.00177.25183957

Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79(1):69-72. 10.1002/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K.9738873

Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267-88. 10.1097/01.gim.0000218152.87434.f3.16702877

Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 2007;26(1):45-8.17915569

Hagemans MLC, Winkel LPF, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671-7. 10.1093/brain/awh384.15659425

Lewandowska E, Wierzba-Bobrowicz T, Rola R, et al. Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study. Folia Neuropathol. 2008;46(2):123-33.18587706

Fukuda T, Roberts A, Ahearn M, et al. Autophagy and Lysosomes in Pompe disease. Autophagy. 2006;2(4):318-20. 10.4161/auto.2984.16874053

Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem. 2001;47(8):1378-83.11468225

An Y, Young SP, Hillman SL, Van Hove JL, Chen YT, Millington DS. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem. 2000;287(1):136-43. 10.1006/abio.2000.4838.11078593

Van der Kraan M, Kroos MA, Joosse M, et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994;203(3):1535-41. 10.1006/bbrc.1994.2360.7945303

Hirschhorn R, Huie ML. Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally “common” in White populations. J Med Genet. 1999;36(1):85-6.9950376

Schoser BG, Müller-Höcker J, Horvath R, et al. Adult-onset glycogen storage disease type 2: clinic-pathological phenotype revisited. Neuropathol Appl Neurobiol. 2007;33(5):544-59.17573812

 


Publication date:
01/13/2016

569642fa5ce02afe0a000000 autopsy Articles

Autops Case Rep

Share this page
Page Sections